Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy.
Héloïse M DelagreverieClaire BauduinNathalie De CastroBeatriz GrinsztejnMarc ChevrierFanélie JouenneSamia MourahIssa KalidiJose Henrique PilottoCarlos BritesNemora Tregnago BarcellosAli AmaraLinda WittkopJean-Michel MolinaConstance DelaugerrePublished in: Open forum infectious diseases (2020)
In participants with HIV and TB, EFV, RAL400, or RAL800 effectively and equally reduced inflammation and HIV-1 DNA levels.
Keyphrases
- antiretroviral therapy
- human immunodeficiency virus
- hiv infected
- hiv infected patients
- hiv positive
- hiv aids
- hepatitis c virus
- hiv testing
- oxidative stress
- men who have sex with men
- mesenchymal stem cells
- single cell
- cell therapy
- circulating tumor
- electronic health record
- single molecule
- circulating tumor cells
- adverse drug